Physician profile
Robert A Forinash
NPI 1639239254
$2,310.06
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $124 · 2021: $933 · 2022: $394 · 2023: $23.69 · 2024: $22.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $367.44 | 2019-2021 | |
| Allergan, INC. | $335.28 | 2019-2020 | |
| Abbvie INC. | $268.82 | 2021 | |
| Alkermes, INC. | $231.25 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $205.07 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $140.47 | 2021-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.39 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $68.06 | 2019 | |
| Noven Therapeutics, LLC | $66.79 | 2021-2022 | |
| Indivior INC. | $61.39 | 2019-2021 | |
| Gilead Sciences, INC. | $56.85 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $48.53 | 2020-2022 | |
| Novo Nordisk INC | $40.48 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $33.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.78 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $28.68 | 2021 | |
| Glaxosmithkline, LLC. | $27.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $25.38 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.59 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $20.39 | 2019 | |
| Philips North America LLC | $20.12 | 2020 | |
| Shire North American Group INC | $19.13 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.96 | 2022 | |
| Neuronetics, INC. | $13.96 | 2019 | |
| Eisai INC. | $12.75 | 2021 | |
| Neos Therapeutics, LP | $12.28 | 2021 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Forinash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.